<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04471727</url>
  </required_header>
  <id_info>
    <org_study_id>HPN328-4001</org_study_id>
    <nct_id>NCT04471727</nct_id>
  </id_info>
  <brief_title>Study in Patients With Advanced Cancers Associated With Expression of DLL3 Who Have Failed Standard Available Therapy</brief_title>
  <official_title>A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN328 in Patients With Advanced Cancers With Expression of DLL3 Who Have Failed Standard Available Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harpoon Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Harpoon Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, Phase 1/2 study of HPN328 as monotherapy to assess the safety, tolerability&#xD;
      and PK in patients with advanced cancers associated with expression of DLL3.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 29, 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Adverse Events by CTCAE 5.0 of HPN 328</measure>
    <time_frame>3 years</time_frame>
    <description>Assess safety and tolerability at increasing dose levels of HPN328 in successive cohorts of patients with solid tumors associated with DLL3 expression by adverse events (CTCAE v5.0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine MTD/RP2D</measure>
    <time_frame>2 years</time_frame>
    <description>Estimate the maximum tolerated dose (MTD) or select the recommended Phase 2 dose (RP2D)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the pharmacokinetics (PK) of HPN328</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluate of levels of HPN328 in blood serum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine preliminary activity of HPN328</measure>
    <time_frame>3 years</time_frame>
    <description>Evaluate preliminary efficacy of HPN328 based on disease assessment using RECISTv1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the immunogenicity</measure>
    <time_frame>3 years</time_frame>
    <description>Evaluate the immunogenicity of HPN328 assessing Anti-drug Antibodies in blood serum</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Small-cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Part 1 (Dose Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HPN328 is IV administered once weekly for about 1 hour. Doses will vary between cohorts as MTD is being determined.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (Dose Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HPN328 is IV administered once weekly for about 1 hour at the recommended phase 2 dose (2) established in Part 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HPN328</intervention_name>
    <description>HPN328 is a tri-specific recombinant protein construct (Tri-specific T Cell Activating Construct [TriTAC®]) containing 3 humanized antibody derived binding domains</description>
    <arm_group_label>Part 1 (Dose Escalation)</arm_group_label>
    <arm_group_label>Part 2 (Dose Expansion)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed malignancy associated with expression of&#xD;
             DLL3:&#xD;
&#xD;
               -  SCLC that has relapsed following at least 1 line of platinum-based chemotherapy&#xD;
&#xD;
               -  Malignancy other than SCLC with pathologic demonstration of high-grade&#xD;
                  neuroendocrine features or demonstration of DLL3 expression in a tumor sample,&#xD;
                  and that the patient has 1 of the following:&#xD;
&#xD;
               -  Disease that is relapsed/refractory to standard systemic therapy,&#xD;
&#xD;
               -  Disease for which standard therapy does not exist, or&#xD;
&#xD;
               -  Disease where standard therapy is not considered appropriate by the Investigator&#xD;
&#xD;
          2. Available archival tissue sample or fresh biopsy tissue sample must be available for&#xD;
             shipment prior to enrollment. Patients with no available tumor tissue, who cannot&#xD;
             safely undergo a biopsy may be eligible if they have documentation of DLL3 expression&#xD;
             in a tumor sample from a prior biopsy.&#xD;
&#xD;
          3. Adequate hematologic status, including:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥1500 cells/μL&#xD;
&#xD;
               -  Platelet count ≥100,000/μL&#xD;
&#xD;
               -  Hemoglobin ≥9 g/dL (no transfusions allowed within 2 weeks prior to screening)&#xD;
&#xD;
          4. Adequate renal function, including:&#xD;
&#xD;
             -Calculated creatinine clearance ≥50 mL/min using the formula of Cockcroft and Gault&#xD;
&#xD;
          5. Adequate liver function, including&#xD;
&#xD;
               -  Total bilirubin ≤1.5 x upper limit of normal (ULN), regardless of direct&#xD;
                  bilirubin, unless the patient has documented Gilbert syndrome in which case the&#xD;
                  maximum total serum bilirubin should be 5 mg/dL&#xD;
&#xD;
               -  Aspartate and alanine transaminase (AST and ALT) ≤3 x ULN&#xD;
&#xD;
        Major Exclusion Criteria:&#xD;
&#xD;
          1. Untreated brain metastases. Participants must have completed treatment for brain&#xD;
             metastasis, and be neurologically stable off steroids, for at least 7 days prior to&#xD;
             first dose of study drug&#xD;
&#xD;
          2. Patients with glioma or other primary CNS malignancy&#xD;
&#xD;
          3. Patients with spinal cord compression or symptomatic/uncontrolled epidural disease.&#xD;
             Patients with previously treated spinal cord compression or epidural disease may be&#xD;
             eligible if stable for at least 1 week prior to first dose of study drug.&#xD;
&#xD;
          4. Active neurologic paraneoplastic syndrome.&#xD;
&#xD;
          5. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent&#xD;
             drainage procedures (e.g., biweekly or more frequently).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Harpoon ClinicalTrials.gov Contact</last_name>
    <phone>650-443-7400</phone>
    <email>hpn328_4001ctgov@harpoontx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josh Saginaw, RN, BSN</last_name>
      <phone>720-848-9281</phone>
      <email>JOSHUA.SAGINAW@CUANSCHUTZ.EDU</email>
    </contact>
    <investigator>
      <last_name>Jose Pacheco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Himisha Beltran, MD</last_name>
      <phone>617-632-2429</phone>
      <email>Himisha_Beltran@DFCI.HARVARD.EDU</email>
    </contact>
    <investigator>
      <last_name>Himisha Beltran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Schneider</last_name>
      <phone>313-576-9749</phone>
      <email>schneidk@karmanos.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RUSHKA KALLICHARAN-SMITH, BA, CCRP</last_name>
      <phone>716-845-1300</phone>
      <phone_ext>2809</phone_ext>
      <email>Rushka.Kallicharan-Smith@RoswellPark.org</email>
    </contact>
    <investigator>
      <last_name>Grace Dy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Schoenfeld, MD</last_name>
      <phone>646-608-4042</phone>
      <email>schoenfa@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Adam Schoenfeld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Information Services</last_name>
      <phone>800-641-2422</phone>
      <email>Kyle.Logue@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Afshin Dowlati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>CanRsrchStudies@providence.org</email>
    </contact>
    <investigator>
      <last_name>Rachel Sanborn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tennessee Oncology Sarah Cannon Research Institute</last_name>
      <phone>615-329-7478</phone>
      <email>cann.researchreferrals@scresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Smitha Menon, MD</last_name>
      <phone>414-805-4600</phone>
      <email>spmenon@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Smitha Menon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 6, 2020</study_first_submitted>
  <study_first_submitted_qc>July 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2020</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung Cancer</keyword>
  <keyword>Small-Cell Lung Cancer</keyword>
  <keyword>DLL3</keyword>
  <keyword>Harpoon</keyword>
  <keyword>TriTAC</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Neuroendocrine Tumors</keyword>
  <keyword>High Grade Neuroendrocrine Features</keyword>
  <keyword>Delta Like Canonical Notch Ligand 3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

